Measurement of psychosine in dried blood spots — a possible improvement to newborn screening programs for Krabbe disease

2015 ◽  
Vol 38 (5) ◽  
pp. 923-929 ◽  
Author(s):  
Coleman T. Turgeon ◽  
Joseph J. Orsini ◽  
Karen A. Sanders ◽  
Mark J. Magera ◽  
Thomas J. Langan ◽  
...  
2013 ◽  
Vol 419 ◽  
pp. 73-76 ◽  
Author(s):  
Wei-Lien Chuang ◽  
Josh Pacheco ◽  
X. Kate Zhang ◽  
Monica M. Martin ◽  
Chad K. Biski ◽  
...  

2006 ◽  
Vol 148 (5) ◽  
pp. 618-622 ◽  
Author(s):  
Richard S. Olney ◽  
Cynthia A. Moore ◽  
Jelili A. Ojodu ◽  
Mary Lou Lindegren ◽  
W. Harry Hannon

2001 ◽  
Vol 47 (8) ◽  
pp. 1378-1383 ◽  
Author(s):  
Kandiah Umapathysivam ◽  
John J Hopwood ◽  
Peter J Meikle

Abstract Background: Pompe disease is an autosomal recessive disorder of glycogen metabolism that is characterized by a deficiency of the lysosomal acid α-glucosidase. Enzyme replacement therapy for the infantile and juvenile forms of Pompe disease currently is undergoing clinical trials. Early diagnosis before the onset of irreversible pathology is thought to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn-screening program. Currently, the clinical diagnosis of Pompe disease is confirmed by the virtual absence, in infantile onset, or a marked reduction, in juvenile and adult onset, of acid α-glucosidase activity in muscle biopsies and cultured fibroblasts. These assays are invasive and not suited to large-scale screening. Methods: A sensitive immune-capture enzyme activity assay for the measurement of acid α-glucosidase protein was developed and used to determine the activity of this enzyme in dried-blood spots from newborn and adult controls, Pompe-affected individuals, and obligate heterozygotes. Results: Pompe-affected individuals showed an almost total absence of acid α-glucosidase activity in blood spots. The assay showed a sensitivity and specificity of 100% for the identification of Pompe-affected individuals. Conclusions: The determination of acid α-glucosidase activity in dried-blood spots is a useful, noninvasive diagnostic assay for the identification of Pompe disease. With further validation, this procedure could be adapted for use with blood spots collected in newborn-screening programs.


2018 ◽  
Vol 21 (7) ◽  
pp. 1644-1651 ◽  
Author(s):  
Thomas J. Langan ◽  
Joseph J. Orsini ◽  
Kabir Jalal ◽  
Amy L. Barczykowski ◽  
Maria L. Escolar ◽  
...  

2004 ◽  
Vol 50 (10) ◽  
pp. 1785-1796 ◽  
Author(s):  
Yijun Li ◽  
C Ronald Scott ◽  
Nestor A Chamoles ◽  
Ahmad Ghavami ◽  
B Mario Pinto ◽  
...  

Abstract Background: Newborn screening for deficiency in the lysosomal enzymes that cause Fabry, Gaucher, Krabbe, Niemann–Pick A/B, and Pompe diseases is warranted because treatment for these syndromes is now available or anticipated in the near feature. We describe a multiplex screening method for all five lysosomal enzymes that uses newborn-screening cards containing dried blood spots as the enzyme source. Methods: We used a cassette of substrates and internal standards to directly quantify the enzymatic activities, and tandem mass spectrometry for enzymatic product detection. Rehydrated dried blood spots were incubated with the enzyme substrates. We used liquid-liquid extraction followed by solid-phase extraction with silica gel to remove buffer components. Acarbose served as inhibitor of an interfering acid α-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed. Results: We analyzed dried blood spots from 5 patients with Gaucher, 5 with Niemann–Pick A/B, 11 with Pompe, 5 with Fabry, and 12 with Krabbe disease, and in all cases the enzyme activities were below the minimum activities measured in a collection of heterozygous carriers and healthy noncarrier individuals. The enzyme activities measured in 5–9 heterozygous carriers were approximately one-half those measured with 15–32 healthy individuals, but there was partial overlap of each condition between the data sets for carriers and healthy individuals. Conclusion: For all five diseases, the affected individuals were detected. The assay can be readily automated, and the anticipated reagent and supply costs are well within the budget limits of newborn-screening centers.


2004 ◽  
Vol 32 (4) ◽  
pp. 741-748 ◽  
Author(s):  
Linda Kharaboyan ◽  
Denise Avard ◽  
Bartha Maria Knoppers

Though in existence for over thirty-five years, due to the increasing panoply of possible tests. Newborn screening programs are drawing public attention. Many jurisdictions have mandatory newborn screening programs for treatable disorders. Disorders are detected through tests on blood spots drawn from a newborn’s heel soon after birth and verified through a diagnostic test with follow-up. Unbeknownst to most parents, these blood spot cards are also stored thereafter. Indeed, while dried blood spots (DBSs) are primarily used for screening for health problems, experience demonstrates that they can be made useful in various contexts unrelated to screening.Newborn dried blood spots have taken on a new life as a result of developments in genetics and the increasing ability of bioinformatics to link DNA information with clinical data. Additionally, storage and secondary uses have been documented to occur without parental consent.


2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Neta Simon ◽  
Jaclyn Shallat ◽  
Corey Williams Wietzikoski ◽  
Whitney E Harrington

Abstract Dried blood spots (DBS) are widely utilized as part of universal newborn screening and as a means of transporting samples from field sites. We use DBS from African field sites to assess for rare maternal-fetal cell exchange during pregnancy known as microchimerism. We aimed to develop a protocol to maximize the quantity of high-quality genomic DNA (gDNA) extracted from DBS. The total gDNA yield obtained from control DBS utilizing a Qiagen-based protocol and a Chelex® 100 resin-based protocol was first compared. Variations of the Chelex® protocol were subsequently tested to develop an optimized protocol. The gDNA was quantified by qPCR targeting the human beta-globin gene. DNA yield for a given experimental condition was normalized to a Chelex® control performed on the same day, and the total yields were compared using a Student’s t-test. The control Chelex® protocol yielded 590% more DNA than the QIAamp® DNA Blood Mini Kit . The absolute efficiency of the control Chelex® protocol was 54%, compared to an absolute efficiency of 9% for the QIAamp® DNA Blood Mini Kit. Modification of the Chelex® protocol to include a second heat precipitation from the same DBS increased the gDNA yield by 29% (P < 0.001). Our optimized protocol including this modification increased the absolute efficiency of extraction to 68%. The gDNA extracted using the Chelex® protocol was stable through repeated freeze–thaw cycles. In a mock microchimerism experiment, rare donor alleles at a frequency of 10 in 100 000 could be identified in gDNA from DBS extracted using the optimized Chelex® protocol. Our findings may be of significance for a diverse range of applications that utilize DBS and require high-quality DNA, including newborn screening programs, pathogen and drug resistance screening from remote field sites, forensics, and rare allele detection.


2014 ◽  
Vol 111 (2) ◽  
pp. S75
Author(s):  
Dietrich Matern ◽  
Coleman C. Turgeon ◽  
Joseph J. Orsini ◽  
Karen A. Sanders ◽  
Jennifer L. Hesemann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document